Short answer
Exelixis Inc (EXEL) filed its Q1 2018 10-Q quarterly report on May 2, 2018 for the quarter ended Mar 30, 2018.
Exelixis Inc Q1 2018 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $212.3M, up from $80.9M YoY, driven by product revenue $134.3M and collaboration revenue $78.1M
- CABOMETYX revenue $128.9M, up from $62.4M, while COMETRIQ declined to $5.3M from $6.5M
- Gross margin increased, with no actual percentage figures disclosed in the provided text
- Operating cash flow $71.8M vs $68.9M YoY, cash and investments $525.6M vs $457.2M
- Outlook: higher 2018 R&D spending, reimbursement pressure, competition, and dependence on CABOMETYX commercialization and approvals
Risk Factors
- Newly added healthcare compliance risk: AKS, false claims, pricing transparency, and GDPR violations could trigger fines, exclusion, sanctions, or corrective oversight
- Most materially updated generic competition risk: FDA’s February 2018 cabozantinib bioequivalence guidance may signal an ANDA investigation
- Near-term market risk: advanced RCC competition from immune checkpoint inhibitor combinations threatens CABOMETYX’s positioning
- Financial risk: $525.6 million cash and investments, including $523.6 million available for operations, may require additional capital for pipeline expansion
- Operational risk: planned second-quarter 2018 headquarters relocation could disrupt operations and increase employee turnover
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Exelixis Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.